catalyst · primary record
Lumateperone high dose + Lumateperone low dose + Placebo
Phase readout · 2027-06-21 · Irritability Associated With Autism Spectrum Disorder
| Company | Intra-Cellular Therapies, Inc. |
|---|---|
| Ticker | Not stated |
| Impact | high |
| Detail | P3 primary completion · NCT06706674 |
| Source | ClinicalTrials.gov |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:56:19.456Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: Intra-Cellular Therapies, Inc.:Lumateperone high dose + Lumateperone low dose + Placebo:2027-06-21:P3 primary completion · NCT06706674
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.